A Superior Genetic Engineering Platform
Welcome The Greffex Story
Greffex’s platform is the world’s most successful gene therapy delivery vehicle (vector) with broad applications for delivering treatments including vaccines, immune suppression and gene therapy.
Highlights
- Founded in 2005 to pursue disruptive and proprietary technology Greffex’s founders first explored in 1998
- Awarded patents in 2014 for the creation of a fully-deleted, helper-independent adenoviral vector platform
- Greffex vectors are clean, safe, stable, versatile, and manufactured in a standardized, cost efficient process
- When applied to vaccines, the universally applicable platform eliminates the need for refrigeration and it can produce doses more quickly, with less lead time, and more cheaply than traditional vaccines
- NIH-sponsored third-party animal trials demonstrated an impressive 100% protection against a deadly pandemic influenza strain (versus FDA standard of 70% in animals and 40% in humans)
- Using the target disease’s genetic sequence, Greffex can create any vaccine in 3-4 weeks and produce 100 million doses in 90 days at a fraction of the cost of traditional vaccine production
- Greffex presently holds 12 patents with 9 additional filings
Patents
Greffex presently holds 12 patents with 9 additional filings
Doses
We can produce 100 million doses in 90 days at a fraction of the cost of traditional vaccine production
The Greffex Platform
Latest News
Neil Bush Joins Board of Directors At Greffex
Houston, Tx. June 4th 2020 Greffex, a pioneering vaccine and gene therapy company based in Houston, Texas, welcomes Mr. Neil Bush to its Board of Directors. “Neil understands the need for a global perspective to make an impact in a post pandemic world,” said Co-Chairman John Price, also President and CEO of Greffex. Mr. Bush […]
Our Team
John R. Price
President and Chief Executive Officer
Uwe D. Staerz
Chief Scientific Officer
William S. Connolly
Executive Vice President